Cyplasin Biomedical Ltd Announces Second U.S. Patent for Cyplasin
"This patent is an important milestone to define our intellectual property for the production method of the cytotoxic cyplasin and related proteins and its application as a substance to treat cancer. With the two US patents now in our possession, the Company will concentrate all its efforts to achieve a fast and successful development of cyplasin", said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.